TW432046B - 2-(arylphenyl) amino-imidazoline derivatives - Google Patents

2-(arylphenyl) amino-imidazoline derivatives Download PDF

Info

Publication number
TW432046B
TW432046B TW087114724A TW87114724A TW432046B TW 432046 B TW432046 B TW 432046B TW 087114724 A TW087114724 A TW 087114724A TW 87114724 A TW87114724 A TW 87114724A TW 432046 B TW432046 B TW 432046B
Authority
TW
Taiwan
Prior art keywords
light
emitting surface
optical lens
light emitting
central
Prior art date
Application number
TW087114724A
Other languages
English (en)
Inventor
Keith Roger Bley
Robin Douglas Clark
Alam Jahangir
Bruce Andrew Kowalczyk
Francisco Javier Lopez-Tapia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of TW432046B publication Critical patent/TW432046B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lenses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

M432046 之左邊緣之距離大於左側出光面之曲率半徑之一半，右 延伸面與右侧出光面之右邊緣之距離大於右側出光面 之曲率半徑之一半。 在本創作的一實施例中，中央出光面、左侧出光 面及右側出光面於厚度方向上呈凸弧狀。 在本創作的一實施例中，複數個光學透鏡相互連 接而形成一光學透鏡陣列結構，且入光面相互連接為一 平面。 在本創作的一實施例中，光學透鏡之相互連接處 形成有一溝槽。 在本創作的一實施例中，更包括一固定件，設置 於光學透鏡陣列結構之邊緣位置處。 本創作對照先前技術之功效 經由本創作所採用之技術手段，光學透鏡之入光 面為一平面，而可增加收光量，減少入光的損失，以提 昇入光效能，降低光源的能源浪費。出光面分為中央出 光面以及中央出光面之兩側所分別延伸連接的左側出 光面與右侧出光面，而可分別設計各出光面的曲率及中 心軸角度並相互搭配，使通過左右與中央出光面而折射 出之光線具有不同出光型態，以配合使用者不同的使用 需求。本創作之光學透鏡能解決現有LED光源在使用 上的問題，將LED光源所發射的光線加以調整，能改 善LED照明亮度、角度不適當的問題，藉由集中發散 角度過大的光線，使自入光面中央下方之點光源所發射 而由光學透鏡投射出之光線，其光線之散逸相較不使用 本創作之光學透鏡時相對地減少，並使LED光源之照 明光型調整至所需的範圍，以符合行車安全等法規的規 定0 5 M432046 本創作所採用的具體實施例，將藉由以下之實施 例及附呈圖式作進一步之說明。 【實施方式】 同時參閱第1圖及第3圖所示，第1圖係顯示本創 作之第一實施例之光學透鏡之立體圖，第2圖係顯示第 1圖之橫向剖面圖，第3圖係顯示第1圖之縱向剖面圖。 本創作之光學透鏡1具有一入光面11及一相對於入光 面11的出光面12,以供設置於入光面11之後方之一光 源2所發射之光線L由入光面11進入光學透鏡1而自 光學透鏡1之出光面12發射出。入光面11為一平面， 出光面12具有一中央出光面121、一左侧出光面122 及一右側出光面123，且中央出光面121分別經由一左 延伸面13與一右延伸面14而在中央出光面121之出光 方向之前方分別延伸連接左側出光面122與右側出光 面 123。 在本實施例中，光源2為一 LED光源，設置於入 光面11中央之後方，LED光源所發射出的光線L之發 光角度0 —般而言不超過120° 。光學透鏡1為一透明 玻璃，光學透鏡1也可為其他折射率大於1的透光材 質，如水晶或類似物。在本實施例中，中央出光面121、 左側出光面122、及右側出光面123為一凸弧面。當光 源2所發射出之光線L由入光面11進入光學透鏡1後， 由於光學透鏡1的材質的折射率大於大氣，故光線L在 大氣中的入射角度大於在光學透鏡1中的折射角度，所 以光線L於入光面11會朝向中央偏折。當光線L而自 光學透鏡1之出光面12折射出時，光線L在光學透鏡 1的出射角度則會小於大氣中的折射角，所以光線L於 6 光與會再度朝向t央偏折。且光線匕於 光角度財央出光面121之曲率半徑 R2iiIt#A1㈤角度、左側出光面122之曲率半徑 八心軸A2的角度、及右側出光面12 關。而在本實施例= 之曲率半徑以小於中央出光面⑵之 山+&R1，且右側出光面123之曲率半徑R3小於中 央出光面121之曲率半徑R卜而左側出光自122之中 心軸A2與中央出光面121之中心軸Al為延伸交會於 中士出光面之曲率中心c的後方，而右側出光面曰 123 之心軸A3與中央出光面121之中心軸A1為延伸交 會於中央出光面m之曲率中心c的後方。藉此而使光 線L於光學透鏡1的出光方向為朝向前方照射。 且由於自光源2所發射出之光線L越靠近兩侧則 強度越弱。在本實施例中，因左側出光面122之曲率半 徑R2及右側出光面123之曲率半徑R3小於中央出光 面121之曲率半徑R1，所以自左側出光面122所投射 出之光線L2及右側出光面123所投射出之光線L3相 較於中央出光面所投射出之光線L1之密集度較大，從 而具有較好的聚光效果，使光源2的所投射出之光線l 之強度於中央及左右兩側能均勻地分佈。並且，左延伸 面13與右延伸面14之距離D1小於中央出光面pi之 曲率半徑R1，使自光源2所發射出之光線L中之靠近 兩側而強度較弱之部分充份地投射至聚光效果較強的 左側出光面122及右側出光面123。 而為了避免光線L由光學透鏡1之左邊緣面15或 右邊緣面16折射出而使光線l向左右兩側散逸，左延 伸面13與左側出光面122之左邊緣1221的距離D2大 於左側出光面122之曲率半徑R2之一半，且右延伸面 14與右侧出光面123之右邊緣1231的距離D3大於右 側出光面123之曲率半徑R3之一半’使光學透鏡丨、左 側發光角最大之光線從左側出光面122發射出，而光學
透鏡1右側發光角最大之光線從右側出光面丨23發射 出。 X 在本實施例中，左延伸面13及右延伸面14為垂 直於入光面11之平面’使經由中央出光面121垂直出 射之光線L1不會行進通過左延伸面13及右延伸面 14°而中央出光面121、左側出光面122及右侧出光面 123於厚度方向上呈凸弧狀，如第3圖所示，使厚度方 向上之光線亦呈現聚光現象。 參閱第4圖及所示，其係顯示本創作之第二實施 例之光學透鏡之橫向剖面圖。此一實施例之光學透鏡 h與前述第一實施例之結構大致相同，故相同或相對 應之構件以相同的元件符號標示，且對於這些部分在下 面的說明中將不再贅述。第二實施例與前述第一實施例 之差異主要在於，左側出光面122a之曲率半徑R4大中 央出光面121之曲率半徑R1，右侧出光面123a之曲率 半徑R5大於中央出光面121之曲率半徑R1。並且，左 侧出光面122a之中心軸A4與中央出光面121之中心轴 A1為延伸交會於中央出光面pi之曲率中心C的前 方’而右侧出光面123a之中心軸A5與中央出光面121 之中心軸A1為延伸交會於中央出光面121之曲率中心 C的前方，藉此使光線L的出光方向為朝向前方照射。 參閱第5圖所示，其係顯示本創作之第三實施例 之光學透鏡之橫向别面圖。此一實施例之光學透鏡1 b 與前述第一實施例之結構大致相同，而第三實施例與前 M432046 述第一實施例之差異主要在於，左側出光面122b之曲 率半徑R6及右侧出光面123b之曲率半徑R7相同於中 央出光面121之曲率半徑R1。 參閱第6圖所示，其係顯示本創作之光學透鏡陣 列結構之立體圖。複數個光學透鏡1相互連接形成一光 學透鏡陣列結構3,而可供複數個光源（圖未示）分別設 置於光學透鏡陣列結構3之每個光學透鏡1之後方，使 每個光源之光線分別由個別的光學透鏡1投射出而朝 向前方照射。且入光面11相互連接為一平面，以使每 個個別的光源所經由個別的光學透鏡1所發射出之光 線於相同高度入射於光學透鏡陣列結構3，並達到增加 收光量而減少光損之效果。此一光學透鏡陣列結構3尤 其適合於複數個不同顏色之光源，以分別地將不同顏色 之光線投射出，而不會產生不同顏色之光線彼此之間的 干涉現象。每個光學透鏡1之相互連接處形成有一溝槽 31，而利用溝槽31以便於清楚地觀測出各個光學透鏡 1所搭配的各個光源之投射區域的邊界。光學透鏡陣列 結構3更包括一固定件32,設置於光學透鏡陣列結構3 之邊緣位置處，以便於將光學透鏡陣列結構3安裝於其 它物件上。 由以上之實施例可知，本創作所提供之光學透鏡 確具產業上之利用價值，故本創作業已符合於專利之要 件。惟以上之敘述僅為本創作之較佳實施例說明，凡精 於此項技藝者當可依據上述之說明而作其它種種之改 良，惟這些改變仍屬於本創作之創作精神及以下所界定 之專利範圍中。 【圖式簡單說明】 9 第2 創作之第1施例之光學透鏡之立體圖 ^ 2圖鋪不第丨圖之撗 瑕圖 第3圖係顯示第1圖之縱 ‘ 第5圖係實施例之光學透鏡之橫向剖面I 第^係顯示本創作之光學透鏡陣列結構之立體圖⑸面丨 【主要元件符號說明】 第4圖係顯干太鲁丨你面圖 α係顯作之第二實關之光學透鏡之橫向 不創作之第三實施例之光學透籍之糌>二 f圖 1、la、lb 11 12 121 122、 122a、122b 1221 123、 123a、123b 1231 13 14 15 16 2 3 31 32 A1、A2、A3、A4 光學透鏡 入光面 出光面 中央出光面 左側出光面 左邊緣 右侧出光面 右邊緣 左延伸面 右延伸面 左邊緣面 右邊緣面 光源 光學透鏡陣列結構 溝槽 固定件 A5中心轴 M4.32Q46 c 曲率中心 D1、D2、D3 距離 L、LI、L2、L3 光線 R1、R2、R3、R4、 曲率半徑 R5、R6、R7 Θ 角度 M432046 ___ ·♦ I公告本 新型專利說明書 ______- (本說明書格式、順序，請勿任意更動，※記號部分請勿填寫） ※申請案號： ※申請日： ※工PC分類：V0厶U006.0!) 100.10. 1 9 一、新型名稱：（中文/英文） 光學透鏡 . 二、中文新型摘要： 一種光學透鏡，具有一入光面及一相對於入光面的出 光面，入光面為一平面，出光面具有一中央出光面、一左 ® 側出光面及一右側出光面，且中央出光面分別經由一左延 伸面與<右延伸面而在中央出光面之出光方向之前方分別 延伸連接左侧出光面與右側出光面，以改變光線路徑，而 達到減少光線散逸、光線投射亮度均勻等效果。 三、英文新型摘要： 1 M432Q46 六、申請專利範圍： L光"®種具有—人光面及—相對於該入光面的 弁而、_^入光面係為一平面，該出光面具有一中央出 、—左側出光面及—右側出光面，且 左延伸面與一右延伸面而梅== 向之心分別延伸連接該左側以面與該右側出 該左側出光面之中妯 午千^工時 交會於該中央出：上f:央出光面之中心軸為延伸 = 徑小於該中央出光面二以右= …轴為延伸交會 1項所狀絲魏，射當該左 左側出光面：ΐ 大該中央出光面之曲率半徑時，該 中:轴為延伸交 面之曲率抑大於丄的則方’且當該右側出光 出光面之中心===率半徑時，該右側 該中央出光面之曲料 =方面之中心軸為延伸交會於 4面係如項所叙光學魏，其中該入光 面。 X 申面及。亥右延伸面垂直於該入光 圍第1項所述之光學透鏡，其中該左延 徑。…彡右延伸面之韓係小於料μ光面之曲率半 12 M432046 七、圖式·
第1圖 12 M432046
·-Λ- 122 121 123
Α1 第2圖 M432046
第3圖 M432046
第4圖 M432046
第5圖 M432046
M432046 四、指定代表圖： (一) 本案指定代表圖為：第（1 (二) 本代表圖之元件符號簡單說明： 1 光學透鏡 11 入光面 12 出光面 121 中央出光面 122 左側出光面 123 右側出光面 13 左延伸面 14 右延伸面 15 左邊緣面 16 右邊緣面 M432046 - 101年3月14日修正替換頁 • 6.如申請專利範圍第1項所述之光學透鏡，其中該左延 • 伸面與該左侧出光面之左邊緣之距離係大於該左側出光 面之曲率半徑之一半，該右延伸面與該右侧出光面之右 邊緣之距離係大於該右側出光面之曲率半徑之一半。 7.如申請專利範圍第1項所述之光學透鏡，其中該中央 出光面、該左側出光面及該右侧出光面於厚度方向上係 呈凸弧狀。 • 8.如申請專利範圍第1項所述之光學透鏡，其中複數個 • 該光學透鏡相互連接而形成一光學透鏡陣列結構，且該 φ 入光面係相互連接為一平面。 9. 如申請專利範圍第8項所述之光學透鏡，其中該光學 透鏡之相互連接處形成有一溝槽。 10. 如申請專利範圍第8項所述之光學透鏡，更包括一 固定件，設置於該光學透鏡陣列結構之邊緣位置處。 13
TW087114724A 1997-09-04 1998-09-08 2-(arylphenyl) amino-imidazoline derivatives TW432046B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5780897P 1997-09-04 1997-09-04
US8991698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
TW432046B true TW432046B (en) 2001-05-01

Family

ID=26736908

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087114724A TW432046B (en) 1997-09-04 1998-09-08 2-(arylphenyl) amino-imidazoline derivatives

Country Status (19)

Country Link
EP (1) EP0902018B1 (zh)
JP (1) JP3040752B2 (zh)
KR (1) KR100309191B1 (zh)
CN (1) CN1110484C (zh)
AT (1) ATE402151T1 (zh)
AU (1) AU746480B2 (zh)
CA (1) CA2245755A1 (zh)
CZ (1) CZ278198A3 (zh)
DE (1) DE69839753D1 (zh)
DK (1) DK0902018T3 (zh)
HK (1) HK1019334A1 (zh)
HU (1) HUP9801950A3 (zh)
IL (1) IL125982A (zh)
MA (1) MA26541A1 (zh)
NO (1) NO312294B1 (zh)
NZ (1) NZ331480A (zh)
PT (1) PT902018E (zh)
RU (1) RU2211834C2 (zh)
TW (1) TW432046B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068591A1 (en) 2000-03-16 2001-09-20 F. Hoffmann-La Roche Ag Carboxylic acid derivatives as ip antagonists
BRPI0113162B8 (pt) * 2000-08-08 2021-05-25 Johnson & Johnson compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
WO2002018313A1 (fr) * 2000-08-30 2002-03-07 Kanagawa University Composes modifies a l'oxetane et composes de photopolymerisation issus de ces composes, leur methodes de preparation, et compositions de polymerisation contenant les composes de photopolymerisation
DE60113563T2 (de) * 2000-11-14 2006-07-13 F. Hoffmann-La Roche Ag Substituierte 2-phenylaminoimidazolin-phenyl-ketonderivate als ip-antagonisten
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
EP1622611A1 (en) * 2003-05-01 2006-02-08 F. Hoffmann-La Roche Ag Imidazolin-2-ylaminophenyl amides as ip antagonists
CA2530538A1 (en) * 2003-07-09 2005-01-20 Keith Roger Bley Thiophenylaminoimidazolines as prostaglandin i2 antagonists
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012018980A2 (en) * 2010-08-04 2012-02-09 Yun Michael Shim Compositions and methods for treating inflammatory diseases
EP2890380A2 (en) * 2012-08-29 2015-07-08 Merck Patent GmbH Ddr2 inhibitors for the treatment of osteoarthritis
WO2014143592A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid ip receptors
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
WO2016043260A1 (ja) * 2014-09-19 2016-03-24 塩野義製薬株式会社 環状グアニジンまたはアミジン化合物
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7711390A (nl) * 1977-10-18 1979-04-20 Philips Nv Nieuwe 2-arylimino-hexahydopyrimidinen en - imi- dazolidinen, zouten en complexen daarvan, werk- wijze ter bereiding van de nieuwe verbindingen, alsmede fungicide preparaten op basis van de nieuwe verbindingen.
NL7810350A (nl) * 1978-10-16 1980-04-18 Duphar Int Res Preparaat met groeiregulerende werking en gebruik van dit preparaat in land- en tuinbouw.
ZA801680B (en) * 1979-04-03 1981-03-25 Fujisawa Pharmaceutical Co 2-imidazoline derivatives,process for the preparation thereof and the pharmaceutical composition of the same
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
US4889868A (en) * 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives

Also Published As

Publication number Publication date
HK1019334A1 (en) 2000-02-03
AU8309498A (en) 1999-03-18
MA26541A1 (fr) 2004-12-20
PT902018E (pt) 2008-09-05
AU746480B2 (en) 2002-05-02
DK0902018T3 (da) 2008-10-20
DE69839753D1 (de) 2008-09-04
NO312294B1 (no) 2002-04-22
HU9801950D0 (en) 1998-10-28
IL125982A (en) 2002-09-12
CN1216762A (zh) 1999-05-19
CZ278198A3 (cs) 1999-04-14
IL125982A0 (en) 1999-04-11
JP3040752B2 (ja) 2000-05-15
HUP9801950A2 (hu) 1999-03-29
KR19990029550A (ko) 1999-04-26
ATE402151T1 (de) 2008-08-15
RU2211834C2 (ru) 2003-09-10
NZ331480A (en) 2000-02-28
EP0902018B1 (en) 2008-07-23
JPH11140057A (ja) 1999-05-25
NO984044L (no) 1999-03-05
NO984044D0 (no) 1998-09-03
CA2245755A1 (en) 1999-03-04
HUP9801950A3 (en) 2001-12-28
CN1110484C (zh) 2003-06-04
EP0902018A2 (en) 1999-03-17
KR100309191B1 (ko) 2001-12-12
EP0902018A3 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
TW432046B (en) 2-(arylphenyl) amino-imidazoline derivatives
CN1058790C (zh) 多光源投影仪
WO2011013733A1 (ja) 導光板、導光板の製造方法、面光源装置および液晶表示装置
JP6274790B2 (ja) 照明装置及び光学部材
KR0144686B1 (ko) 배면투사스크린
CN1538201A (zh) 投影显示器
CN1100281C (zh) 光导体、光导体的制造方法以及面光源
US20180284593A1 (en) Rear projection screen
JP2007188065A (ja) 光学素子及び照明装置
CN103471033B (zh) 一种led透镜及其透镜模组
JP5418759B2 (ja) 車両用灯具
WO2004109391A1 (ja) フレネルレンズシート、透過型スクリーン及び背面投射型表示装置
KR20220002531A (ko) 차량용 램프 광학 소자, 차량용 램프 모듈, 차량용 헤드램프 및 차량
US20130322075A1 (en) Optical component and associated illuminating device
JP2004170862A (ja) フレネルレンズ
JP5228998B2 (ja) 車両用灯具
JP5212719B2 (ja) 車両用灯具
CN101629693B (zh) 具有多个复焦点光栅的光分布板材
CN210687860U (zh) 高功率照明装置
CN214174812U (zh) 一种新型倾斜投影装置
CN210688102U (zh) 回复反射照明装置
JP2014175253A (ja) 照明装置
JP3699045B2 (ja) 背面投射型スクリーンにおいて用いられる前面板、前面板付きレンチキュラーレンズシート及び背面投射型スクリーン
US6624933B2 (en) Front faceplate used in rear projection type screen, front-faceplate-equipped lenticular lens sheet, and rear projection type screen
RU2317612C1 (ru) Светодиодное устройство

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent